Groundbreaking SMA Gene Therapy Research in Dubai
Dubai is emerging as a regional hub for rare disease treatment, particularly in Spinal Muscular Atrophy (SMA) gene therapy. In a recent podcast, Dr. Omendra Narayan, Consultant Interventional Paediatric Pulmonologist and Sleep Physician at American Hospital Dubai, discussed his pioneering work in SMA gene therapy. This innovative research is a collaborative effort involving American Hospital Dubai, Medcare Women and Children Hospital, Dubai Health, Mediclinic City Hospital, and the University of Sharjah College of Medicine.
About Dr. Omendra Narayan
Dr. Omendra Narayan is a UK board-certified paediatric pulmonologist with dual CCT in Pediatrics and Pediatric Pulmonology. Since joining American Hospital Dubai in July 2021, he has established the hospital’s Paediatric Pulmonology service and serves as Director of the American Children’s Centre, a specialized paediatric facility.
What is Spinal Muscular Atrophy (SMA)?
SMA is a genetic neuromuscular disorder caused by a deficiency of SMN protein, leading to progressive muscle weakness and motor neuron degeneration. It is classified into five types, with Type 1 SMA (Werdnig-Hoffman disease) being the most severe. Patients with SMA often face challenges in breathing, swallowing, mobility, and motor function.
Globally, SMA affects 1 in 6,000–11,000 live births, with the Middle East reporting a higher incidence due to consanguinity rates. While SMA cannot be prevented, carrier testing, genetic counseling, and early intervention improve patient outcomes.
Gene Therapy for SMA: Onasemnogene Abeparvovec
Onasemnogene abeparvovec is a one-time intravenous gene therapy that delivers a functional copy of the SMN gene using an adenovirus-associated viral vector. Approved in the U.S. in 2019, this therapy is available in the UAE since 2020 at American Hospital Dubai, Al Jalila Children’s Hospital, Medcare Women and Children Hospital, and Fakeeh University Hospital.
Key Benefits:
- Early intervention improves motor function and survival
- Reduces dependency on ventilatory support
- Provides hope even for older SMA patients
The therapy is paired with corticosteroids to manage immune responses and requires precision care from a multidisciplinary team.
SMA Gene Therapy Research in Dubai
Recent studies in Dubai have shown that gene therapy is safe and effective, even in older children or those with intensive ventilatory support:
- Prospective Cohort Study: 22 SMA-1 patients receiving ventilation showed reduced ventilator hours, with 1 patient fully weaned off support after 8 months.
- Retrospective Study: 60 SMA patients demonstrated significant improvements in motor function, reduced hospital admissions, and fewer infections within 3 months of treatment.
These results highlight Dubai’s role in advancing clinical research for rare genetic diseases.
Dubai as a Regional Hub for SMA Gene Therapy
Dubai attracts patients from Turkey, South Asia, North and East Africa, emphasizing the emirate’s leading position in paediatric gene therapy. Hospitals provide multidisciplinary care, advanced ventilatory support, and specialized follow-up, making the city a top destination for rare disease treatment in the Middle East.
Future Research and Rare Disease Innovations in UAE
The UAE continues to support clinical research and gene therapy trials. Ongoing projects aim to expand treatment to a larger cohort of SMA patients and explore therapies for other genetic conditions like Duchenne Muscular Dystrophy. With active ethics and research committees, collaboration across hospitals ensures cutting-edge innovation in paediatric care and gene therapy.
Conclusion
Dubai’s SMA gene therapy research underscores the emirate’s commitment to rare disease innovation and paediatric care excellence. With access to state-of-the-art facilities, expert multidisciplinary teams, and advanced gene therapies, families affected by SMA have renewed hope for improved outcomes and a better quality of life.
